(-)-2,3,5,6-Tetrahydro-6-Phenylimidazo[2,1-B]Thiazole Hydrochloride

In the domain of chiral anthelmintics, the levorotatory enantiomer of tetramisole hydrochloride—chemically designated as (-)-2,3,5,6-tetrahydro-6-phenylimidazo[2,1-b]thiazole hydrochloride—constitutes the pharmacologically active agent widely recognized under the nonproprietary name levamisole hydrochloride. The stereogenic carbon at the 6-position of the fused imidazothiazole ring system dictates bioactivity; the S-configuration alone binds the nicotinic acetylcholine receptor of nematode somatic muscle, inducing sustained depolarization and spastic paralysis. The racemate, tetramisole HCl, contains equal proportions of the dextrorotatory R-isomer (dexamisole), which contributes negligible anthelmintic effect at therapeutic concentrations while retaining a capacity for off-target immunological perturbation. Regulatory monographs therefore mandate precise enantiomeric purity criteria: the USP 43–NF 38 monograph for levamisole hydrochloride specifies a specific optical rotation range of -121.5° to -128.5°, measured at 20°C on a 10 mg/mL aqueous solution, calculated on the anhydrous basis. This specification immediately differentiates the product from bulk tetramisole, which exhibits no net optical rotation and has been largely supplanted in human and companion-animal medicine since the 1980s.

What distinguishes levamisole HCl from the racemic feedstock in process-scale isolation?

Resolution of racemic tetramisole base via diastereomeric salt formation with a chiral acid—historically dibenzoyl-D-tartaric acid or camphorsulfonic acid—remains the principal industrial route. The hydrochloride salt of the isolated S-enantiomer is then recrystallized from a polar solvent system, typically ethanol/water mixtures, to meet pharmacopoeial purity thresholds. Production-scale crystallizers operating at batch volumes exceeding 500 L encounter a critical processing window: cooling rate must be held between 0.3 K/min and 0.8 K/min during the metastable zone to prevent lattice incorporation of the R-antipode. Deviation above this ramp rate consistently yields final dried cake with enantiomeric excess below 99.0%, triggering OOS results under the USP limit test for dexamisole, which employs chiral HPLC on a tris(3,5-dimethylphenylcarbamate)-coated silica column (USP L51) with a mobile phase of hexane/ethanol/diethylamine. The difference between levamisole HCl and unprocessed tetramisole, therefore, is not merely compositional but resides in the existence of a validated, orthogonal purification step that removes the R-isomer to a level below the 1.0% threshold required for human anthelmintic monographs. When production campaigns transition from veterinary-grade to Ph.Eur.-compliant active pharmaceutical ingredient (API), the drying protocol imposes additional constraints. Levamisole hydrochloride dihydrate, the stable crystalline form at ambient relative humidity, undergoes efflorescence below 25% RH at 25°C and converts to the anhydrous form, which is hygroscopic. Vacuum tray dryers operating at 40–45°C with a maximum pressure of 10 kPa achieve water content between 0.8% and 1.2% (Karl Fischer, method Ia per Ph.Eur. 2.5.12), conforming to the dihydrate stoichiometry. Anhydrous levamisole HCl, occasionally requested for non-aqueous formulation, must be dried at 60°C under nitrogen purge for not less than 8 hours, then immediately packaged in aluminum-laminated foil with desiccant. Residual solvents are monitored via headspace GC-FID; the USP <467> option 1 limit for ethanol is 5000 ppm, and for acetone 5000 ppm, while Class 2 solvents such as toluene, if used in the final recrystallization, must not exceed 890 ppm. Tablet compression blends containing levamisole HCl exhibit a pronounced sensitivity to magnesium stearate over-lubrication; mixing times beyond 5 minutes in a V-blender at 25 rpm reduce tablet hardness by up to 35% due to hydrophobic film formation on the platy crystal surfaces, a behavior documented on instrumented rotary presses equipped with 10 mm flat-faced beveled punches operating at 60 rpm.

Immunomodulatory applications and the purity-driven divergence from veterinary imidazothiazoles

Beyond nematode control, levamisole hydrochloride is repurposed as a T-cell-directed immunopotentiator in the adjunctive therapy of colorectal carcinoma (5-fluorouracil plus levamisole regimens, e.g., the Moertel protocol established in 1990) and in pediatric nephrotic syndrome. These human indications impose residual impurity limits absent from veterinary bulk powder specifications. The impurity profile prescribed by Ph.Eur. 10.0 monograph 0727 lists specified impurity A (the 6-phenyl-2,3-dihydroimidazo[2,1-b]thiazole dehydration product) at not more than 0.3%, impurity B (the oxo-degradation product) at not more than 0.2%, and any unspecified impurity at not more than 0.10%. Total impurities cannot exceed 0.5%. Veterinary premix grades, in contrast, are routinely traded with assay specifications of 98.0–102.0% but without comprehensive degradation product profiling, relying on a simple loss-on-drying and sulfated ash specification. A purchaser navigating between these grades must therefore request the vendor’s Certificate of Analysis for the explicit batch under consideration: a 99.5% assay by non-aqueous titration with perchloric acid does not preclude the presence of 0.9% total related substances, which would render the material non-conforming for injectable human dosage forms. The immunomodulatory mechanism itself is susceptible to stereochemical contamination; the R-isomer exhibits antagonist activity at certain adenosine receptor subtypes in murine splenocyte assays, creating a confounding variable in clinical investigations. Published data for the specific interaction of dexamisole with human A2a receptors is limited, but in vitro binding studies using [3H]ZM-241385 at a concentration of 10 µM suggest a Ki exceeding 5 µM, whereas levamisole does not displace the radioligand appreciably. Thus, optically impure levamisole HCl cannot be dismissed as merely diluent; it introduces unpredictable pharmacodynamic interference.

Comparative monograph specifications for levamisole hydrochloride versus tetramisole hydrochloride

Parameter	Levamisole HCl (Ph.Eur. 10.0)	Tetramisole HCl (BP Vet 2020)
Appearance	White or almost white, crystalline powder	White or almost white, crystalline powder
Specific optical rotation (dried substance, 10 mg/mL H₂O, 589 nm, 20°C)	-121.5° to -128.5°	Not specified (racemate, rotation ~0°)
Assay (anhydrous basis, non-aqueous titration)	98.5–101.0%	98.0–102.0%
Related substances (HPLC)	Total impurities ≤ 0.5%, specified impurities A and B individually controlled	Any impurity ≤ 0.5%; total ≤ 1.0%
Loss on drying (100–105°C, 2 h)	1.5–2.5% (dihydrate)	≤ 1.0% (may include anhydrous form)
Sulfated ash	≤ 0.1%	≤ 0.1%
Heavy metals (Method C, Ph.Eur. 2.4.8)	≤ 20 ppm	≤ 20 ppm
Endotoxin (Ph.Eur. 2.6.14), if intended for parenteral use	≤ 2.5 IU/mg	Not routinely required

Dissolution behavior in biorelevant media further differentiates levamisole hydrochloride from generic anthelmintic powders. The compound is freely soluble in water (>50 mg/mL at 25°C), sparingly soluble in ethanol (~10 mg/mL), and practically insoluble in dichloromethane. In fasted-state simulated gastric fluid (FaSSGF, pH 1.6, pepsin 0.1 mg/mL), the intrinsic dissolution rate (USP <711> rotating disk, 100 rpm) exceeds 1.5 mg/min/cm², indicating no solubility-limited absorption risk. Blends intended for prolonged-release matrices, however, encounter a processing conflict: the high aqueous solubility results in rapid surface leaching when coated with ethylcellulose from an organic solvent, generating pinhole defects in the diffusion barrier. Microencapsulation via Wurster fluidized-bed coating (Glatt GPCG-1, inlet air temperature 50°C, spray rate 4 g/min) using an aqueous ethylcellulose dispersion (Surelease E-7-19040) overcomes this, provided the core pellets contain a subcoat of hydroxypropyl methylcellulose (viscosity grade 5 cP, 2% w/w gain) to inhibit drug migration during the aqueous coating process.

When the synthesis pathway alters polymorphic and enantiomeric stability

The crystal lattice of levamisole hydrochloride dihydrate belongs to the orthorhombic space group P2₁2₁2₁, with unit cell parameters a = 7.42 Å, b = 8.19 Å, c = 22.87 Å, as determined by single-crystal X-ray diffraction at 173 K. This lattice accommodates water molecules in channel-like voids, and partial dehydration at temperatures above 45°C in dry atmospheres yields a metastable monohydrate that readily reconverts to the dihydrate upon exposure to ambient moisture. The structural difference is relevant to formulations subjected to wet granulation with high-shear mixers (e.g., Diosna P1-6, impeller speed 300 rpm, chopper 1500 rpm, liquid addition rate 20 mL/min): granule temperature during kneading can momentarily exceed 45°C due to frictional heating, driving partial conversion to the monohydrate and altering granule porosity. This polymorphic shift affects tablet tensile strength after compression on a Korsch XL 100 rotary press, with monohydrate-rich granules exhibiting lower compactibility (Heckel yield pressure increase of ~15 MPa) compared to granules processed below the dehydration threshold. No uniform header opens this next consideration—rather, the focus shifts to the operational boundary associated with amine-containing excipients. Levamisole hydrochloride, being a secondary amine hydrochloride, participates in Maillard-type condensation with reducing sugars such as lactose monohydrate (a common tablet filler). Deterioration of blend content uniformity over time is traceable to the formation of glycosylamine adducts, accelerated at 40°C/75% RH stability conditions. In accelerated studies conducted in HDPE bottles with child-resistant caps, a levamisole HCl (50 mg)/lactose monohydrate (150 mg) binary mix stored for 4 weeks showed 0.8% degradation to an unidentified conjugated impurity, as detected by hydrophilic interaction chromatography (HILIC) with charged aerosol detection. Replacement of lactose with dicalcium phosphate dihydrate (USP, anhydrous basis, 100 mesh) eliminated this degradation pathway. The incompatibility extends to aqueous media at alkaline pH: above pH 8.5, the free base precipitates as a crystalline solid with a melting point of 89–91°C, clogging liquid filling nozzles during suspension manufacturing. This precipitation threshold must be observed when combining levamisole HCl with alkaline buffering agents such as trisodium phosphate dodecahydrate.

Comparative dissolution profiles across pH conditions for levamisole HCl immediate-release tablets (USP apparatus 2, 50 rpm, 900 mL)

Medium	15 min release (%)	30 min release (%)	45 min release (%)
0.1 N HCl (pH 1.2)	98.2 ± 1.1	99.1 ± 0.8	99.4 ± 0.5
Acetate buffer (pH 4.5)	95.7 ± 1.3	97.8 ± 0.9	98.3 ± 0.7
Phosphate buffer (pH 6.8)	93.0 ± 1.5	96.2 ± 1.2	97.1 ± 1.0

Production records from a cGMP-compliant facility manufacturing levamisole HCl for export markets reveal that the most frequent batch failure in multi-ton campaigns originates not from assay shortfall but from a specific test: chloride content by potentiometric titration (Ph.Eur. 2.5.23). The theoretical chloride content for C₁₁H₁₂N₂S·HCl·2H₂O is 14.7%. Batches drying in a fluidized-bed drier (Aeromatic MP-1) with insufficient post-drying cooling exhibited chloride values of 15.2–15.8%, indicative of anhydrous or monohydrate conversion and over-drying. The corrective action involved maintaining outlet air temperature at 35°C and terminating drying when product temperature reached 33°C, monitored via an in-line NIR moisture probe (Foss XDS, wavenumber region 4000–8000 cm⁻¹, PLS model with SECV 0.12%). This process adjustment reduced the chloride OOS rate from 3.2% to 0.4% of consecutive batches. The distinction between levamisole hydrochloride and its generic counterparts in the anthelmintic class—such as albendazole, mebendazole, or pyrantel pamoate—is primarily mechanistic and resistance-profile-related. Levamisole acts as a nicotinic agonist selective for the N-subtype ionotropic receptor; nematodes resistant to benzimidazoles (which bind β-tubulin) often retain susceptibility to the imidazothiazole nucleus. However, levamisole resistance in Haemonchus contortus and Teladorsagia circumcincta is associated with a single-nucleotide polymorphism in the acr-8 gene, reducing receptor subunit expression. This resistance mechanism does not confer cross-resistance to closantel or monepantel, but it has become endemic in sheep farms across Australia and the UK since 2010. Therefore, the product’s current veterinary utility is frequently as a component of combination drench formulations rather than a stand-alone agent. From a quality control perspective, the specific rotation determination described in USP <781> requires strict temperature control of the polarimeter cell: a deviation of ±1°C in a 1 dm cell alters observed rotation by approximately 0.5°, potentially shifting a borderline -121.0° result into the conforming range only if measurement temperature is precisely 20.0°C and pH of the aqueous solution is between 5.0 and 6.5. The monographs do not mandate a specific model of polarimeter, but laboratories operating Rudolph Autopol IV with TempTrol or equivalent Peltier-based cell holders achieve the required inter-laboratory reproducibility. The assay by non-aqueous titration (Ph.Eur. 2.2.20) uses 0.1 M perchloric acid in glacial acetic acid/formic acid (1:1) with crystal violet indicator; the end-point is faint blue, and automatic titrators with photometric sensors (Metrohm Titrando 907) eliminate operator bias in borderline cases. In bulk packaging for intercontinental shipment, the product is filled into UN-approved fiber drums with double polyethylene liners (LDPE, thickness 0.15 mm) and sealed under nitrogen. Container closure integrity testing per USP <1207> confirms a leak diameter threshold of 15 µm using laser-based headspace analysis. Shipments traversing tropical maritime routes without temperature-controlled containers have recorded internal container temperatures of 55°C for periods exceeding 24 hours; under such conditions, the dihydrate partially melts in its own water of crystallization, forming a fused cake that requires mechanical delumping before further processing. This behavior contrasts with the anhydrous form, which remains free-flowing but adsorbs moisture upon opening, emphasizing that the grade selected must match the intended processing environment and equipment capability. Where levamisole hydrochloride is incorporated into medicated livestock feed pellets, uniform distribution is challenged by the compound’s electrostatic charging tendency (triboelectric series position near nylon) when passed through pneumatic conveying lines at velocities above 15 m/s. Operators install static-dissipative ionizing bars at transfer points to reduce surface charge to below 0.5 kV, a threshold above which segregation in gravity-fed mixers becomes measurable. Premix concentrates at 1 kg/tonne require a stepwise geometric dilution: the 0.1% active premix is first blended with 5 kg of ground corn (800 µm median particle size) in a ribbon mixer for 10 minutes, then incorporated into the final feed matrix. This method, validated by tracer studies using ferrous sulfate recovery (95–105% acceptance), differs from simpler direct addition procedures used with less potent anthelmintic powders, where a single-stage blending step suffices. The scope of application for levamisole hydrochloride continues to include niche areas such as the treatment of bovine parasitic bronchitis (Dictyocaulus viviparus) and as an adjuvant in chronic hepatitis B therapy in certain jurisdictions, though the latter use remains off-label in many regions. Regardless of the intended use, the material’s compliance with identity, impurity, and enantiomeric purity criteria as detailed in a current Certificate of Analysis against the Ph.Eur. or USP monograph remains the only objective basis for product acceptance. Every shipment should be cross-referenced against storage condition +15°C to +25°C, with an excursion allowance up to 30°C not exceeding 72 cumulative hours, as stipulated in manufacturer stability protocols derived from ICH Q1A(R2) guidelines.